Juvenile myoclonic epilepsy (JME) is characterized by the presence of bilateral myoclonic, generalized myoclonic, tonic–clonic, and (less often) absence seizures. Its prevalence comprises 5–10% of all epilepsies and 18% of genetic (idiopathic) generalized epilepsies [1]. Clinical symptoms occur between 6 and 22 years of age, most frequently during adolescence: age at onset is 13–16 years in half of affected patients [2]. Myoclonic seizures primarily occur between 12 and 18 years of age; these consist of generalized tonic–clonic (GTC) seizures in 80–97% of patients [3].
23
JUN
JUN
0